Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-667 pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma and slow early response
2023-504821-38-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR) in SER participants by risk group. Planned start Sep 2019; status: authorised.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2023-504821-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504821-38-00.